{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T09:33:23Z","timestamp":1793093603098,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.semarthrit.2023.152256","type":"journal-article","created":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T21:06:26Z","timestamp":1692651986000},"page":"152256","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Studying the Role of C5-Inhibition Therapy in Scleroderma Renal Crisis-Induced Thrombotic Microangiopathy \u2013 A Review of Literature"],"prefix":"10.1016","volume":"63","author":[{"given":"Larabe","family":"Farrukh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia D.","family":"Steen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swati","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.semarthrit.2023.152256_bib0001","doi-asserted-by":"crossref","first-page":"137","DOI":"10.5301\/jsrd.5000249","article-title":"Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities","volume":"2","author":"Varga","year":"2017","journal-title":"Journal of Scleroderma and Related Disorders"},{"issue":"Suppl 119","key":"10.1016\/j.semarthrit.2023.152256_bib0002","first-page":"S3","article-title":"One year in review 2019: systemic sclerosis","volume":"37","author":"Barsotti","year":"2019","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2023.152256_bib0003","first-page":"202","article-title":"Scleroderma (systemic sclerosis): classification, subsets and pathogenesis","volume":"15","author":"LeRoy","year":"1988","journal-title":"The Journal of rheumatology"},{"issue":"7","key":"10.1016\/j.semarthrit.2023.152256_bib0004","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.3390\/jpm12071123","article-title":"Kidney involvement in systemic sclerosis","volume":"12","author":"Reggiani","year":"2022","journal-title":"Journal of Personalized Medicine"},{"issue":"2","key":"10.1016\/j.semarthrit.2023.152256_bib0005","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0889-857X(03)00016-4","article-title":"Scleroderma renal crisis","volume":"29","author":"Steen","year":"2003","journal-title":"Rheumatic Disease Clinics"},{"issue":"8","key":"10.1016\/j.semarthrit.2023.152256_bib0006","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/qjmed\/hcm052","article-title":"Scleroderma renal crisis: patient characteristics and long-term outcomes","volume":"100","author":"Penn","year":"2007","journal-title":"QJM: An International Journal of Medicine"},{"issue":"3","key":"10.1016\/j.semarthrit.2023.152256_bib0007","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/BOR.0000000000000604","article-title":"Management of scleroderma renal crisis","volume":"31","author":"Nagaraja","year":"2019","journal-title":"Current Opinion in Rheumatology"},{"issue":"6","key":"10.1016\/j.semarthrit.2023.152256_bib0008","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/ckj\/sfv101","article-title":"Eculizumab for rescue of thrombotic microangiopathy in PM-Scl antibody-positive autoimmune overlap syndrome","volume":"8","author":"Thomas","year":"2015","journal-title":"Clinical Kidney Journal"},{"issue":"30","key":"10.1016\/j.semarthrit.2023.152256_bib0009","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000004459","article-title":"Complement activation and effect of eculizumab in scleroderma renal crisis","volume":"95","author":"Devresse","year":"2016","journal-title":"Medicine"},{"key":"10.1016\/j.semarthrit.2023.152256_bib0010","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/6051083","article-title":"Scleroderma renal crisis debute with thrombotic microangiopathy: a successful case treated with eculizumab","volume":"2018","author":"Uriarte","year":"2018","journal-title":"Case Reports in Nephrology"},{"issue":"4","key":"10.1016\/j.semarthrit.2023.152256_bib0011","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.ekir.2021.01.021","article-title":"Role of C5 inhibition in Idiopathic Inflammatory Myopathies and Scleroderma Renal Crisis\u2013Induced Thrombotic Microangiopathies","volume":"6","author":"Gouin","year":"2021","journal-title":"Kidney International Reports"},{"key":"10.1016\/j.semarthrit.2023.152256_bib0012","doi-asserted-by":"crossref","DOI":"10.1177\/23247096221074591","article-title":"Scleroderma Renal Crisis Associated With Microangiopathic Hemolytic Anemia in a Patient With Seronegative Scleroderma and Monoclonal Gammopathy","volume":"10","author":"Riley","year":"2022","journal-title":"Journal of Investigative Medicine High Impact Case Reports"},{"issue":"11","key":"10.1016\/j.semarthrit.2023.152256_bib0013","article-title":"Scleroderma Renal Crisis With Thrombotic Microangiopathy Treated With Eculizumab","volume":"14","author":"Saba","year":"2022","journal-title":"Cureus"},{"issue":"8S","key":"10.1016\/j.semarthrit.2023.152256_bib0014","first-page":"S355","article-title":"Scleroderma renal crisis complicating male-to-female transgender hormonal therapy in a patient with long-standing and stable limited cutaneous systemic sclerosis","volume":"27","author":"Arneson","year":"2021","journal-title":"JCR: Journal of Clinical Rheumatology"},{"key":"10.1016\/j.semarthrit.2023.152256_bib0015","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.rmcr.2018.08.010","article-title":"Atypical rapid onset scleroderma renal crisis (SRC) complicated with diffuse alveolar hemorrhage and pleuro-pericardial effusions in a patient with recently diagnosed breast cancer and a positive anti-RNA polymerase III Ab.: a case report","volume":"25","author":"Bukamur","year":"2018","journal-title":"Respiratory medicine case reports"},{"key":"10.1016\/j.semarthrit.2023.152256_bib0016","doi-asserted-by":"crossref","first-page":"A4272","DOI":"10.1164\/ajrccm-conference.2022.205.1_MeetingAbstracts.A4272","article-title":"A Crisis of Complement? Scleroderma Renal Crisis Treated with Complement Inhibition","author":"Rhoads","year":"2022","journal-title":"C46. RHEUMATOLOGY, RENAL, NEUROLOGY, AND GASTROENTEROLOGY CASES."},{"key":"10.1016\/j.semarthrit.2023.152256_bib0017","doi-asserted-by":"crossref","first-page":"e936116","DOI":"10.12659\/AJCR.936116","article-title":"Thrombotic Microangiopathy Secondary to Systemic Sclerosis with Severe Complement Activation Not Responsive to Eculizumab: A Case Report","volume":"23","author":"Nakamura","year":"2022","journal-title":"The American Journal of Case Reports"},{"key":"10.1016\/j.semarthrit.2023.152256_bib0018","first-page":"16385","article-title":"Atypical hemolytic-uremic syndrome due to a scleroderma renal crisis treated with eculizumab","author":"Skonieczny","year":"2022","journal-title":"Polish Archives of Internal Medicine"},{"issue":"3","key":"10.1016\/j.semarthrit.2023.152256_bib0019","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.rcreue.2019.08.002","article-title":"Eculizumab as a therapeutic option for patients with scleroderma renal crisis associated with hemolytic uremic syndrome","volume":"27","author":"Bucheli","year":"2020","journal-title":"Revista Colombiana de Reumatolog\u00eda (English Edition)"},{"issue":"6","key":"10.1016\/j.semarthrit.2023.152256_bib0020","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/art.40809","article-title":"Generation of a core set of items to develop classification criteria for scleroderma renal crisis using consensus methodology","volume":"71","author":"Butler","year":"2019","journal-title":"Arthritis & Rheumatology"},{"key":"10.1016\/j.semarthrit.2023.152256_bib0021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11926-015-0551-y","article-title":"Recent developments in the classification, evaluation, pathophysiology, and management of scleroderma renal crisis","volume":"18","author":"Ghossein","year":"2016","journal-title":"Current rheumatology reports"},{"issue":"2","key":"10.1016\/j.semarthrit.2023.152256_bib0022","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1053\/j.ackd.2019.11.002","article-title":"Complement and renal thrombotic microangiopathy associated with hypertension and scleroderma","volume":"27","author":"Zuckerman","year":"2020","journal-title":"Advances in Chronic Kidney Disease"},{"key":"10.1016\/j.semarthrit.2023.152256_bib0023","article-title":"Scleroderma renal crisis","volume":"44","author":"Bose","year":"2015"},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152256_bib0024","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/mr\/roac028","article-title":"Management review of scleroderma renal crisis: An update with practical pointers","volume":"33","author":"Foocharoen","year":"2023","journal-title":"Modern Rheumatology"},{"issue":"12","key":"10.1016\/j.semarthrit.2023.152256_bib0025","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1093\/rheumatology\/kez435","article-title":"Classifications of scleroderma renal crisis and reconsideration of its pathophysiology","volume":"58","author":"Yamashita","year":"2019","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.semarthrit.2023.152256_bib0026","doi-asserted-by":"crossref","first-page":"162","DOI":"10.5152\/eurjrheum.2020.20048","article-title":"Scleroderma renal crisis: Case reports and update on critical issues","volume":"8","author":"Zanatta","year":"2021","journal-title":"European Journal of Rheumatology"},{"key":"10.1016\/j.semarthrit.2023.152256_bib0027","doi-asserted-by":"crossref","DOI":"10.3899\/jrheum.220752","article-title":"The Role of Complement in Autoimmune Disease-Associated Thrombotic Microangiopathy and the Potential for Therapeutics","author":"Java","year":"2023","journal-title":"The Journal of Rheumatology"},{"key":"10.1016\/j.semarthrit.2023.152256_bib0028","series-title":"Current Progress in Nephrology","first-page":"181","article-title":"Chapter 10\u2013Thrombotic microangiopathy","author":"Java","year":"2022"},{"key":"10.1016\/j.semarthrit.2023.152256_bib0029","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ekir.2020.10.009","article-title":"Complement in secondary thrombotic microangiopathy","volume":"6","author":"Palma","year":"2020","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.semarthrit.2023.152256_bib0030","first-page":"1","article-title":"Renal disease and systemic sclerosis: an update on scleroderma renal crisis","author":"Cole","year":"2022","journal-title":"Clinical Reviews in Allergy & Immunology"},{"key":"10.1016\/j.semarthrit.2023.152256_bib0031","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-016-1168-x","article-title":"Analysis of complement biomarkers in systemic sclerosis indicates a distinct pattern in scleroderma renal crisis","volume":"18","author":"Okr\u00f3j","year":"2016","journal-title":"Arthritis research & therapy"},{"key":"10.1016\/j.semarthrit.2023.152256_bib0032","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/543704","article-title":"Scleroderma renal crisis: a pathology perspective","volume":"2010","author":"Batal","year":"2010","journal-title":"International journal of rheumatology"},{"key":"10.1016\/j.semarthrit.2023.152256_bib0033","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1590\/2175-8239-jbn-3807","article-title":"Complement activation in atypical hemolytic uremic syndrome and scleroderma renal crisis: a critical analysis of pathophysiology","volume":"40","author":"Zuckerman","year":"2018","journal-title":"Brazilian Journal of Nephrology"},{"issue":"3","key":"10.1016\/j.semarthrit.2023.152256_bib0034","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.humpath.2008.08.001","article-title":"Renal biopsy findings predicting outcome in scleroderma renal crisis","volume":"40","author":"Batal","year":"2009","journal-title":"Human pathology"},{"issue":"9","key":"10.1016\/j.semarthrit.2023.152256_bib0035","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.autrev.2018.03.012","article-title":"Therapy of scleroderma renal crisis: State of the art","volume":"17","author":"Zanatta","year":"2018","journal-title":"Autoimmunity Reviews"},{"issue":"3","key":"10.1016\/j.semarthrit.2023.152256_bib0036","first-page":"205","article-title":"Eculizumab as a therapeutic option in patients with scleroderma renal crisis associated with haemolytic uraemic syndrome","volume":"27","author":"Miranda","year":"2020","journal-title":"Revista Colombiana de Reumatolog\u00eda"},{"key":"10.1016\/j.semarthrit.2023.152256_bib0037","doi-asserted-by":"crossref","first-page":"A4272","DOI":"10.1164\/ajrccm-conference.2022.205.1_MeetingAbstracts.A4272","article-title":"A Crisis of Complement? Scleroderma Renal Crisis Treated with Complement Inhibition. InC46","author":"Rhoads","year":"2022","journal-title":"RHEUMATOLOGY, RENAL, NEUROLOGY, AND GASTROENTEROLOGY CASES"},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152256_bib0038","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1053\/j.ajkd.2013.07.011","article-title":"Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases","volume":"63","author":"Fakhouri","year":"2014","journal-title":"American journal of kidney diseases"},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152256_bib0040","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3390\/cells10010148","article-title":"Complement as a therapeutic target in systemic autoimmune diseases","volume":"10","author":"Galindo-Izquierdo","year":"2021","journal-title":"Cells"},{"issue":"5","key":"10.1016\/j.semarthrit.2023.152256_bib0041","first-page":"106","article-title":"UK Scleroderma Study Group (UKSSG) guidelines on the diagnosis and management of scleroderma renal crisis","volume":"34","author":"Lynch","year":"2016","journal-title":"Clinical and experimental rheumatology"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017223000987?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017223000987?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:11:15Z","timestamp":1758733875000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017223000987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":40,"alternative-id":["S0049017223000987"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2023.152256","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Studying the Role of C5-Inhibition Therapy in Scleroderma Renal Crisis-Induced Thrombotic Microangiopathy \u2013 A Review of Literature","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2023.152256","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"152256"}}